Boosted Atazanavir Stands Up to Kaletra
"These study results were a topic of discussion for many, since all
previous studies of atazanavir (Reyataz) were done with it as an
unboosted drug, and no one had anticipated its effectiveness being
similar to Kaletra (lopinavir/ritonavir) as a result of boosting."
Cal Cohen, M.D., reports.
FTC Compares Well to d4T When Combined With ddI
The newest antiretroviral on the block, emtricitabine (FTC, Emtriva),
looks good in comparison to d4T (stavudine, Zerit) when either is
taken in combination with both ddI (didanosine, Videx) and efavirenz
(Sustiva). However, more comparisons are needed to really show the
strengths and weaknesses of this newly approved medication, reports
Paul Sax, M.D.
Africa: Oral Contraceptives Increase HIV Risk
In Kenya, a significant association was found between oral contraceptive use and infection with HIV, a rate 50 percent higher than that of women using no contraceptive or surgical sterilization.
Switching Out d4T Helps Some Reverse Lipoatrophy
Lipoatrophy (also known as wasting) has been associated with many
HIV medications. In this study, a significant number of people with
lipoatrophy reported improvement when the d4T (stavudine, Zerit) in
their regimens was replaced with either AZT (zidovudine, Retrovir)
or abacavir (Ziagen). Paul Sax, M.D., reports.
Rosiglitazone: Wasting Treatment?
Rosiglitazone may be effective in increasing body fat in patients
with fat wasting. Mark Holodniy, M.D., reports.
Abacavir/3TC/Tenofovir Fails as Naive Therapy
In a small study, the combination of abacavir/3TC/tenofovir failed
to work in the majority of treatment-naive patients -- 58 percent
experienced virologic failure by week eight. Timothy Wilkin, M.D.,
More Evidence Ties Heart Problems to Protease Inhibitors
Evidence mounts linking cardiovascular complications to the use
of protease inhibitors. Gerald Pierone, Jr., M.D., reports on this sizeable study, the latest to analyze the effect of HAART on lipid levels.
Superinfection More Common Than First Thought
HIV "superinfection" -- infection with more than one HIV strain in a single person -- may be more common than once believed, a finding that could complicate HIV/AIDS vaccine development.
Tenofovir Has Better Side-Effect Profile Than d4T
Results at 96 weeks show tenofovir (Viread) still the winner against
d4T (stavudine, Zerit) in the side effect gamble -- especially in regards to mitochondrial problems like peripheral neuropathy, lipodystrophy and lactic acidosis. Paul E. Sax, M.D., reports.
Importance of Resistance Testing
Dr. Daniel Kuritzkes, a prominent AIDS researcher, emphasized at
IAS 2003 that resistance testing was an adjunct to -- not a replacement for -- clinical judgment when making decisions about HIV treatment. Mark Holodniy, M.D., reports.
Efavirenz-Based Regimens Generally Beat Older PI-Based Regimens
A study on switching HAART regimens shows that once-daily regimens
based on efavirenz (Sustiva) were more effective and more tolerable
than most older protease inhibitor-based regimens.
A Look at Twenty Years of HIV Research
The quest for knowledge about HIV has been an "extraordinary journey,"
NIAID director Dr. Anthony Fauci told scientists Monday.